Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Liver transplantation with the Meld system: a prospective study from a single European center.

Ravaioli M, Grazi GL, Ballardini G, Cavrini G, Ercolani G, Cescon M, Zanello M, Cucchetti A, Tuci F, Del Gaudio M, Varotti G, Vetrone G, Trevisani F, Bolondi L, Pinna AD.

Am J Transplant. 2006 Jul;6(7):1572-7.

2.

Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.

Ravaioli M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Zanello M, Ballardini G, Varotti G, Vetrone G, Tuci F, Lauro A, Ramacciato G, Pinna AD.

Transplantation. 2006 Feb 27;81(4):525-30.

PMID:
16495798
3.

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.

Liver Transpl. 2007 Jun;13(6):857-66.

4.

Survival benefit after liver transplantation: a single European center experience.

Ravaioli M, Grazi GL, Dazzi A, Bertuzzo V, Ercolani G, Cescon M, Cucchetti A, Masetti M, Ramacciato G, Pinna AD.

Transplantation. 2009 Sep 27;88(6):826-34. doi: 10.1097/TP.0b013e3181b26807.

PMID:
19920783
5.

Impact of model for end-stage liver disease on patient survival and disease-free survival in patients receiving liver transplantation for hepatocellular carcinoma.

Moonka D, Castillo E, Kumer S, Abouljoud M, Divine G, Pelletier S.

Transplant Proc. 2009 Jan-Feb;41(1):216-8. doi: 10.1016/j.transproceed.2008.09.060.

PMID:
19249517
6.

Model for End-Stage Liver Disease (MELD) system to allocate and to share livers: experience of two Italian centers.

Ravaioli M, Masetti M, Dazzi A, Romano A, Spaggiari M, Grazi GL, Ercolani G, Cescon M, Di Gioia P, De Ruvo N, Montalti R, Ballarin R, Di Benedetto F, Ridolfi L, Alvaro N, Ramacciato G, Morelli C, Gerunda E, Pinna AD.

Transplant Proc. 2008 Jul-Aug;40(6):1814-5. doi: 10.1016/j.transproceed.2008.05.053.

PMID:
18675057
7.

Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?

Cuomo O, Perrella A, Arenga G.

Transplant Proc. 2008 Jul-Aug;40(6):1906-9. doi: 10.1016/j.transproceed.2008.05.072.

PMID:
18675085
8.
9.

The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis.

Dutkowski P, Oberkofler CE, Béchir M, Müllhaupt B, Geier A, Raptis DA, Clavien PA.

Liver Transpl. 2011 Jun;17(6):674-84. doi: 10.1002/lt.22228.

10.

Laboratory test variability and model for end-stage liver disease score calculation: effect on liver allocation and proposal for adjustment.

Ravaioli M, Masetti M, Ridolfi L, Capelli M, Grazi GL, Venturoli N, Di Benedetto F, Bianchi FB, Cavrini G, Faenza S, Begliomini B, Pinna AD, Gerunda GE, Ballardini G.

Transplantation. 2007 Apr 15;83(7):919-24.

PMID:
17460563
11.

The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.

Freitas AC, Itikawa WM, Kurogi AS, Stadnik LG, Parolin MB, Coelho JC.

Arq Gastroenterol. 2010 Jul-Sep;47(3):233-7.

12.

Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Ioannou GN, Perkins JD, Carithers RL Jr.

Gastroenterology. 2008 May;134(5):1342-51. doi: 10.1053/j.gastro.2008.02.013. Epub 2008 Feb 13.

PMID:
18471511
13.

Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V.

Am J Transplant. 2006 Aug;6(8):1957-62. Epub 2006 Jun 9.

14.

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.

Liver Transpl. 2004 Jan;10(1):36-41.

15.

Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation.

Gotthardt D, Weiss KH, Baumgärtner M, Zahn A, Stremmel W, Schmidt J, Bruckner T, Sauer P.

BMC Gastroenterol. 2009 Sep 25;9:72. doi: 10.1186/1471-230X-9-72.

16.

Model for End-Stage Liver Disease (MELD) score and organ allocation from cadaveric donors for 198 liver transplantation procedures performed in a single center.

Santori G, Andorno E, Morelli N, Casaccia M, Bottino G, Ghirelli R, Valente U.

Transplant Proc. 2008 Jul-Aug;40(6):1903-5. doi: 10.1016/j.transproceed.2008.05.016.

PMID:
18675084
17.

Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.

Pestana RC, Baracat EI, Massarollo PC, Pereira LA, Szutan LA.

Transplant Proc. 2013 Jul-Aug;45(6):2111-4. doi: 10.1016/j.transproceed.2012.11.007. Epub 2013 Jun 5.

PMID:
23747144
18.

The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience.

Schaffer RL 3rd, Kulkarni S, Harper A, Millis JM, Cronin DC 2nd.

Liver Transpl. 2003 Nov;9(11):1211-5.

19.

Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era.

Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, Shaked A, Furth E, Reddy KR, Olthoff K.

Liver Transpl. 2006 Apr;12(4):665-73.

20.

Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.

Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, Kim YJ, Yoon JH, Lee HS, Lee KU.

Liver Transpl. 2009 May;15(5):496-503. doi: 10.1002/lt.21606.

Supplemental Content

Support Center